Nephrotoxicity of Chloroquine and Hydroxychloroquine in COVID-19 Patients.
作者信息
Mahmoudi Javad, Sadigh-Eteghad Saeed, Salehi-Pourmehr Hanieh, Gharekhani Afshin, Ziaee Mojtaba
机构信息
Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Research Center for Evidence-Based Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
出版信息
Adv Pharm Bull. 2021 Jan;11(1):6-7. doi: 10.34172/apb.2021.022. Epub 2020 Nov 7.
Abstract
摘要
相似文献
1
Nephrotoxicity of Chloroquine and Hydroxychloroquine in COVID-19 Patients.氯喹和羟氯喹对新冠肺炎患者的肾毒性
Adv Pharm Bull. 2021 Jan;11(1):6-7. doi: 10.34172/apb.2021.022. Epub 2020 Nov 7.
2
Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin.羟氯喹/氯喹治疗 COVID-19 的影响：一枚硬币的两面。
J Interferon Cytokine Res. 2020 Oct;40(10):469-471. doi: 10.1089/jir.2020.0105. Epub 2020 Sep 1.
3
[Hydroxychloroquine and chloroquine for COVID-19: no evidence of effectiveness].[羟氯喹和氯喹治疗新冠病毒病：无有效性证据]
Ned Tijdschr Geneeskd. 2020 Jun 2;164:D5141.
4
Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19.将知名药物重新用于抗病毒治疗：羟氯喹和氯喹——从 HIV-1 感染到 COVID-19。
Expert Rev Anti Infect Ther. 2020 Nov;18(11):1119-1133. doi: 10.1080/14787210.2020.1792291. Epub 2020 Jul 13.
5
Chloroquine and COVID-19: Should We Care about Ototoxicity?氯喹与2019冠状病毒病：我们应该关注耳毒性吗？
Int Arch Otorhinolaryngol. 2020 Jul;24(3):e359-e363. doi: 10.1055/s-0040-1714142. Epub 2020 Jul 31.
6
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.氯喹和羟氯喹作为对抗新型冠状病毒肺炎的现有武器。
Int J Antimicrob Agents. 2020 Apr;55(4):105932. doi: 10.1016/j.ijantimicag.2020.105932. Epub 2020 Mar 4.
7
[Hydroxychloroquine. Cardiology's viewpoint in times of coronavirus pandemic].[羟氯喹啉。冠状病毒大流行时期心脏病学的观点]
Medicina (B Aires). 2020;80(3):271-274.
8
Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?羟氯喹啉/氯喹啉在预防新型冠状病毒感染（COVID-19）方面还有未来吗？
Ann Rheum Dis. 2021 Feb;80(2):e19. doi: 10.1136/annrheumdis-2020-217570. Epub 2020 Apr 21.
引用本文的文献
1
Impact of Acute Kidney Injury on the COVID-19 In-Hospital Mortality in Octogenarian Patients: Insights from the COVOCA Study.急性肾损伤对八旬患者新型冠状病毒肺炎住院死亡率的影响：来自COVOCA研究的见解
Life (Basel). 2024 Jan 4;14(1):86. doi: 10.3390/life14010086.
2
Risk Factors and Clinical Characteristics of Acute Kidney Injury in Patients with COVID-19: A Systematic Review and Meta-Analysis.新型冠状病毒肺炎患者急性肾损伤的危险因素及临床特征：一项系统评价和荟萃分析
Pathophysiology. 2023 May 15;30(2):233-247. doi: 10.3390/pathophysiology30020020.
3
Hypertension related toxicity of chloroquine explains its failure against COVID-19: Based on rat model.氯喹与高血压相关的毒性解释了其抗COVID-19失败的原因：基于大鼠模型。
Front Pharmacol. 2022 Nov 30;13:1051694. doi: 10.3389/fphar.2022.1051694. eCollection 2022.
4
An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients.一项评估氯喹/羟氯喹在重症 COVID-19 患者中的疗效的开放性随机对照试验。
Sci Rep. 2021 Apr 27;11(1):9023. doi: 10.1038/s41598-021-88509-9.
本文引用的文献
1
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.追踪 SARS-CoV-2 刺突蛋白的变化：D614G 增加 COVID-19 病毒感染力的证据。
Cell. 2020 Aug 20;182(4):812-827.e19. doi: 10.1016/j.cell.2020.06.043. Epub 2020 Jul 3.
2
Bradykinin as a Probable Aspect in SARS-Cov-2 Scenarios: Is Bradykinin Sneaking out of Our Sight?缓激肽可能是新冠病毒感染情况中的一个因素：缓激肽是否在我们的视线中悄然溜走？
Iran J Allergy Asthma Immunol. 2020 May 17;19(S1):13-17. doi: 10.18502/ijaai.v19i(s1.r1).2850.
3
Increasing host cellular receptor-angiotensin-converting enzyme 2 expression by coronavirus may facilitate 2019-nCoV (or SARS-CoV-2) infection.冠状病毒增加宿主细胞表面受体血管紧张素转化酶 2 的表达可能有助于 2019-nCoV（或 SARS-CoV-2）感染。
J Med Virol. 2020 Nov;92(11):2693-2701. doi: 10.1002/jmv.26139. Epub 2020 Jul 2.
4
Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase.将瑞德西韦重新定位为针对新型冠状病毒肺炎（COVID-19）RNA依赖性RNA聚合酶的核苷酸类似物的研发。
J Biomol Struct Dyn. 2021 Jul;39(10):3771-3779. doi: 10.1080/07391102.2020.1767210. Epub 2020 May 20.
5
Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China.中国 26 例 COVID-19 死亡患者的肾脏组织病理分析。
Kidney Int. 2020 Jul;98(1):219-227. doi: 10.1016/j.kint.2020.04.003. Epub 2020 Apr 9.
6
Kidney disease is associated with in-hospital death of patients with COVID-19.肾病与 COVID-19 患者住院期间的死亡相关。
Kidney Int. 2020 May;97(5):829-838. doi: 10.1016/j.kint.2020.03.005. Epub 2020 Mar 20.
7
Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection.慢性肾脏病与2019冠状病毒病（COVID-19）严重感染相关。
Int Urol Nephrol. 2020 Jun;52(6):1193-1194. doi: 10.1007/s11255-020-02451-9. Epub 2020 Mar 28.
8
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.抗炎药物在治疗重症新型冠状病毒病 2019（COVID-19）患者中的应用：来自中国临床免疫学家的观点。
Clin Immunol. 2020 May;214:108393. doi: 10.1016/j.clim.2020.108393. Epub 2020 Mar 25.
9
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
10
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).羟氯喹治疗严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的体外抗病毒活性和优化剂量设计预测。
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
Zotero 插件